The Fly On the Wall
ARIAD price target raised to $10 from $7 at Stifel
Stifel raised its price target for ARIAD shares to $10 after the FDA said the company can resume marketing of Iclusig in the U.S. Stifel views the FDA's approval positively for the European Medicine Agency's review ofIclusig which started on December 5. The firm expects a quick uptake in U.S. sales.
thanks past poster- read article from Wall Street and concurs
Market News Call
CytRx Corporation (NASDAQ:CYTR) The company on Dec. 11 announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable soft tissue sarcomas (STS). Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in theblood to allow for delivery of higher amounts of doxorubicin (3½ to 4 times) without the major dose-limiting toxicities seen with administration of doxorubicin alone.
Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
By Lee Jackson January 9, 2014
Celldex Therapeutics Inc. (NASDAQ: CLDX) focuses on developing therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines. Investors are interested in Celldex because of the unmet need therapies the company is developing. Celldex is working on drug indications that include therapies for glioblastoma, breast cancer, dense deposit disease and lymphoma. A recent secondary stock offering helped shore up the company coffers. The company is to update its CDX-1135 drug status, whichcould be a huge catalyst. The Oppenheimer price target is set at $40. The Thomson/First Call estimate is in line at $39.
CLDX Immune Drug Results Came Out Early and After Hours Went Up $7, Shorts Were trapped. This Is Bigger Catalyst, Shorts Are going To get Trapped, results anytime now